4月22日,药明巨诺(02126)发布公告,宣布公司与主要股东之一的Juno于2025年4月18日签订了许可协议。根据该协议,公司将向Juno授予JWsLVV生产工艺及相关技术知识的非独家许可,涉及的技术知识与Juno细胞治疗产品的开发、商业化和制造密切相关。由于协议项下的交易代价超过5%,因此需要遵循上市规则的相关规定,包括独立股东的批准。根据许可协议,Juno将在协议生效后45天内向公司支付...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.